Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Down 70.6% in June

Posted by Doug Wharley on Jul 12th, 2026

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR – Get Free Report) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 65,392 shares, a decline of 70.6% from the June 15th total of 222,527 shares. Currently, 7.1% of the company’s shares are short sold. Based on an average daily volume of 5,387,370 shares, the short-interest ratio is presently 0.0 days.

Cuprina Holdings (Cayman) Trading Down 6.0%

CUPR stock traded down $0.32 during mid-day trading on Friday, hitting $4.97. 31,012 shares of the stock were exchanged, compared to its average volume of 5,210,070. The firm’s fifty day simple moving average is $3.57. Cuprina Holdings has a 12 month low of $1.76 and a 12 month high of $76.00. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 0.07.

Cuprina Holdings (Cayman) (NASDAQ:CUPR – Get Free Report) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cuprina Holdings (Cayman) has a consensus rating of “Sell”.

View Our Latest Stock Analysis on Cuprina Holdings (Cayman)

About Cuprina Holdings (Cayman)

(Get Free Report)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.